Mainboard-listed LMA International NV, the provider of supraglottic airway management devices, says it is in advanced talks to acquire Wolfe Tory Medical, a Salt Lake City, Utah-based manufacturer and distributor of medical devices.

The expected cash consideration for the acquisition is US$13.1 million ($17.3 million), plus additional deferred payments based on the 2012 trailing sales of two new products that will be introduced in 2011. But the proposed acquisition will not include Wolfe Tory Medical’s critical care product, AbViser.

LMA expects to conclude negotiations and enter into a definitive “merger” agreement in relation to the proposed acquisition on or around Dec 31 2010 after Wolfe Tory Medical has obtained approval from its shareholders for the sale.

William Crothers, Group CEO of LMA, says: “LMA’s chief interest in Wolfe Tory Medical (which develops a range of anaesthesia, critical care, and emergency application devices) is contained in its line of Mucosal Atomization Devices (MAD) that represents over 75% of the company’s sales. These consumable products are primarily sold to physicians in two of LMA’s strongest call points – anaesthesiologists and emergency room physicians.”

The newly acquired MAD products will be distributed through LMA’s US, subsidiary, LMA North America Inc, which has a sales force four times the size of Wolfe Tory Medical’s current operations. The products will also be sold through the firm’s highly regarded International Distributor network that reaches over 100 countries worldwide.